For instance, monalizumab and the anti-PDL-1 inhibitor durvalumab is currently undergoing phase II clinical testing for NSCLC with PD-1 immune checkpoint resistance (NCT03833440) and a phase III clinical trial for patients with stage III unresectable NSCLC (NCT05221840) [65]. Here, CD274 is linked to non-small cell lung carcinoma.